TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32519032
Drug: 6MP tablet
Normalized name: 2-Amino 6MP
DrugBank: Tioguanine (DB00352)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6MP tablet (50 mg)
Study: 32835607
Drug: EM-β-carotene (emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: EM-β-carotene (emulsion dispersion formulation)
Study: 32835607
Drug: CR-β-carotene (crystal
Approvals — FDA: no, EMA: no, PMDA: no
Description: CR-β-carotene (crystal dispersion formulation)
Study: 34029707
Drug: Extended infusion
Normalized name: Extended Infusion Set 6mm Cannula 23" Tubing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended infusion (EI)
Study: 34564759
Drug: Dexmedetomidine 1
Normalized name: DEXMEDETOMIDINE 120MCG SUBLINGUAL FILM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 1 µg/kg
Study: 36260325
Drug: hsTnT increase
Normalized name: Incruse
Approvals — FDA: no, EMA: no, PMDA: no
Description: hsTnT increase of 7 ng/L or more
Study: 36260325
Drug: Stable hsTnT
Normalized name: Heat stable ricin vaccine
DrugBank: Heat stable ricin vaccine (DB18477)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stable hsTnT values (change <3 ng/L)
Study: 39636024
Drug: Oral moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral moxifloxacin
Study: 32459420
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of oral dronabinol
Study: 34119499
Drug: Prophylaxis +
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylaxis + cefazolin 2 g IV × 3 followed by oral amoxicillin/clavulanate 3 g/day (Group B)
Study: 34119499
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (Prophylactic cefazolin 2 g IV)
Study: 34119499
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (Prophylaxis + cefazolin 2 g IV × 3 followed by oral amoxicillin/clavulanate 3 g/day)
Study: 35490404
Drug: BAY 1831865
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 1831865 (3.5, 7, 17, 35, 75, or 150 mg i.v. or 150 mg s.c.)
Study: 36096984
Drug: Sorafenib 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib 400 mg orally twice daily continuously
Study: 33905902
Drug: Combined administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined administration of 2% lidocaine and 0.5% bupivacaine (20 mL mixture: 10 mL each)
Study: 33905902
Drug: Sequential administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential administration of 2% lidocaine (10 mL) followed by 0.5% bupivacaine (10 mL) after 120 s
Study: 33905902
Drug: Combined administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined administration of 2% lidocaine and 0.5% bupivacaine
Study: 34813038
Drug: Total radiation
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total radiation dose in closure group
Study: 34813038
Drug: Total radiation
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total radiation dose in nonclosure group
Study: 33811400
Drug: 1% phytic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% phytic acid solution and EndoSequence BC sealer
Study: 33811400
Drug: 17% EDTA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17% EDTA solution and EndoSequence BC sealer
Study: 32251400
Drug: Nivolumab monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab monotherapy (3 patients in safety run-in)
Study: 34060166
Drug: Cutaneous stimulation
Normalized name: follicle stimulating hormone / luteinizing hormone Injection [Menopur]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cutaneous stimulation therapy
Study: 32118696
Drug: Chronic low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chronic low-dose carbon monoxide (CO) administration
Study: 34399066
Drug: Spirulina supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirulina supplementation (6 g/day for 21 days)
Study: 37055702
Drug: i-gel
Normalized name: Di-Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: i-gel
Study: 36000374
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A eye gel combined with 3M transparent tape
Study: 36000374
Drug: Erythromycin eye
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin eye ointment combined with 3M transparent tape
Study: 32913021
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg escitalopram × 2 weeks
Study: 32913021
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg escitalopram × 8 weeks
Study: 32913021
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg escitalopram × 8 weeks
Study: 36301305
Drug: Parent-Adolescent (PA)
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent-Adolescent (PA) treatment condition
Study: 32089456
Drug: LDL-C goal
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL-C goal <50 mg/dL for all patients in secondary prevention or very high-risk primary prevention; optional goal ≤30 mg/dL for category A extreme-risk patients; recommended goal ≤30 mg/dL for category B extreme-risk patients.
Study: 39315857
Drug: FACT-G
Approvals — FDA: no, EMA: no, PMDA: no
Description: FACT-G
Study: 32382685
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no drug)
Study: 34133856
Drug: Tofacitinib (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib (10 mg twice daily for up to 14 days)
Study: 34133856
Drug: Placebo (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (twice daily for up to 14 days)
Study: 36008352
Drug: Fluid volume
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid volume quartile 4 (1258-2790 ml)
Study: 36008352
Drug: Fluid administration
Normalized name: Fluid Administration Set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid administration of 1000 ml starting at least 1 hour before contrast injection and continuing for 6 hours
Study: 36008352
Drug: Mean fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mean fluid volumes <964 ml
Study: 34320864
Drug: Fluorouracil 1%
Normalized name: FLUOROURACIL 1% CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorouracil 1% cream
Study: 34157578
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg methotrexate (MTX) per week
Study: 32470924
Drug: NZBC extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: NZBC extract (CurraNZ™) 300 mg/day
Study: 36329165
Drug: Fluorescein Angiography
Normalized name: Fluorescein
DrugBank: Fluorescein (DB00693)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluorescein Angiography (FA) guided laser treatment
Study: 34953042
Drug: Standard induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard induction chemotherapy
Study: 33514869
Drug: Low-dose group
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose group (100 ml of Lactobacillus casei strain Shirota)
Study: 32324471
Drug: Block-structured training
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Block-structured training alternating weekly between blood flow restricted low-load resistance training (BFR-RT) at 20% 1-RM and heavy-load resistance training (HL-RT) at 70-90% 1-RM (BFR-HRT, n = 9)
Study: 35926074
Drug: Curated social
Normalized name: Safety 1st Social Safety Pack KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curated social web app for COVID-19 vaccine information
Study: 33077275
Drug: High fibre
Normalized name: Adult high protein high fibre formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fibre flatbread with enzymatically released free FA (14.22 mg)
Study: 33077275
Drug: Standard high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard high fibre bread (2.34 mg)
Study: 33077275
Drug: White bread
Normalized name: White bread
Approvals — FDA: no, EMA: no, PMDA: no
Description: White bread control (0.48 mg)
Study: 39438214
Drug: Lidocaine infusion
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine infusion
Study: 36204877
Drug: Ethanol injection
Normalized name: ethanol Injection
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol injection combined with 125I radioactive seed implantation
Study: 36204877
Drug: Ethanol injection
Normalized name: ethanol Injection
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol injection alone
Study: 32183895
Drug: Placebo (dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (dosage not specified)
Study: 36123843
Drug: Dexamethasone injection
Normalized name: dexamethasone Injection
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone injection preoperatively
Study: 36123843
Drug: Dexamethasone injection
Normalized name: dexamethasone Injection
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone injection preoperatively and topical honey application
Study: 34032731
Drug: Puerarin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Puerarin (150 mg/d for 3 months)
Study: 35089372
Drug: lidocaine 0.5
Normalized name: LIDOCAINE 0.5% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: lidocaine 0.5 mg/kg (Group III)
Study: 35089372
Drug: lidocaine 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: lidocaine 1.0 mg/kg (Group IV)
Study: 33049411
Drug: Oral TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral TXA (1 g at 4, 10, and 16 hours postoperatively)
Study: 33049411
Drug: Intravenous TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous TXA (0.5 g at 6, 12, and 18 hours postoperatively)
Study: 36437383
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg rosuvastatin plus 10 mg ezetimibe
Study: 36437383
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg rosuvastatin alone
Study: 36437383
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ezetimibe alone
Study: 36437383
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ezetimibe plus 10 mg rosuvastatin
Study: 34101900
Drug: Calcifediol 0.266
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcifediol 0.266 mg/month for 12 months
Study: 34101900
Drug: Calcifediol 0.266
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcifediol 0.266 mg/month for 4 months followed by placebo for 8 months
Study: 32912942
Drug: Probiotic Peanut
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic Peanut Oral ImmunoTherapy (PPOIT)
Study: 38047365
Drug: Treatment-as-Usual (TAU)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-Usual (TAU)
Study: 33203026
Drug: Extreme learning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extreme learning based solutions
Study: 33549732
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy intervention
Study: 32184653
Drug: IV morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV morphine
Study: 32367867
Drug: Tramadol 50
Normalized name: traMADol 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 50 mg (Group T)
Study: 32367867
Drug: Saline 4
Normalized name: DRESSING,WET SALINE 4IN X 8IN KEN#3606
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 4 ml (Group S)
Study: 38787930
Drug: Intravenous thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thrombolysis (IVT)
Study: 32769878
Drug: AZL‐M 80 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZL‐M 80 mg
Study: 32769878
Drug: AZL‐M 40 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZL‐M 40 mg
Study: 32769878
Drug: valsartan 160 mg
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: valsartan 160 mg
Study: 33722866
Drug: Free distribution
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free distribution of medicines
Study: 37461207
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A
Study: 37461207
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment B
Study: 36239788
Drug: No chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No chemotherapy (Control)
Study: 37158751
Drug: no treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: no treatment (control)
Study: 34930617
Drug: veliparib during
Normalized name: veliparib
DrugBank: Veliparib (DB07232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: veliparib during chemotherapy and maintenance (veliparib-throughout)
Study: 36341232
Drug: Standard-care (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-care (low FODMAP diet, Otilonium Bromide 1 tablet TID, multi-strain probiotic 1 capsule BID for 1 month)
Study: 32152145
Drug: Ciliary neurotrophic
Normalized name: CILIARY NEUROTROPHIC FACTOR
DrugBank: Ciliary neurotrophic factor (DB05344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciliary neurotrophic factor (CNTF) treatment
Study: 33985435
Drug: Severe chemotherapy-induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Severe chemotherapy-induced neutropenia (CIN)
Study: 33985435
Drug: Mild chemotherapy-induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild chemotherapy-induced neutropenia (CIN)
Study: 33985435
Drug: Severe and
Normalized name: Daytime Severe and Nighttime Severe cold and flu KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Severe and mild chemotherapy-induced neutropenia (CIN) in out-of-landmark group
Study: 35410754
Drug: Selumetinib granule
Normalized name: selumetinib
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selumetinib granule (25 mg)
Study: 35410754
Drug: Selumetinib capsule
Normalized name: selumetinib
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selumetinib capsule (50 mg [2 x 25 mg])
Study: 36641027
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (NT)
Study: 34531537
Drug: Ibrutinib 420
Normalized name: ibrutinib 420 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib 420 mg once daily
Study: 34687308
Drug: Dry needling
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry needling with conventional physical therapy
Study: 34687308
Drug: Sham dry
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham dry needling with conventional physical therapy
Study: 34370612
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy (control group)
Study: 34992881
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose radiation therapy (RT)
Study: 36310517
Drug: Multimodal physiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multimodal physiotherapy intervention (exercise therapy and patient education)
Study: 39691747
Drug: Standard analgesic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard analgesic treatment
Study: 35425844
Drug: Control (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (3 mL of subcutaneous 0.5% bupivacaine)
Study: 35425844
Drug: HVIGI (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: HVIGI (10 mL of 0.5% bupivacaine and 30 mL of normal saline, ultrasound‐guided between tendon and underlying fat pad)
Study: 35425844
Drug: HVIGI with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: HVIGI with steroid (0.25 mL of 100 mg/mL hydrocortisone)
Study: 34008857
Drug: Perampanel 4
Normalized name: perampanel 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perampanel 4 mg
Study: 34008857
Drug: Perampanel 8
Normalized name: perampanel 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perampanel 8 mg
Study: 35247102
Drug: Continuing ARB/CCB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuing ARB/CCB combination tablets (Group C)
Study: 35247102
Drug: Withholding ARB/CCB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withholding ARB/CCB combination tablets (Group W)
Study: 34220581
Drug: Ketamine hydrochloride
Normalized name: Ketamine Hydrochloride
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketamine hydrochloride (0.5 mg/kg)
Study: 34780683
Drug: Milvexian (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milvexian (all doses)
Study: 33419635
Drug: Weekly subcutaneous
Normalized name: Weekly Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly subcutaneous semaglutide
Study: 34551146
Drug: Hydrophobic narrow-diameter
Normalized name: narrowleaf marshelder pollen extract
DrugBank: Iva angustifolia pollen (DB10968)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrophobic narrow-diameter implants (Neoporos surface, NS)
Study: 34551146
Drug: Hydrophilic narrow-diameter
Normalized name: narrowleaf marshelder pollen extract
DrugBank: Iva angustifolia pollen (DB10968)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrophilic narrow-diameter implants (Acqua surface, AS)
Study: 33593462
Drug: Synbiotic ice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synbiotic ice cream supplementation for 30 days containing 2·1 × 10^8 CFU/g for Lactobacillus acidophilus LA‐5, 2·7 × 10^9 CFU/g for Bifidobacterium animalis BB‐12, and 2·3 g of inulin in 60 g of ice cream.
Study: 33593462
Drug: Placebo ice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ice cream.
Study: 33593462
Drug: Synbiotic ice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synbiotic ice cream supplementation.
Study: 34789539
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiation therapy
Study: 34789539
Drug: Standard systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard systemic treatment
Study: 37644215
Drug: Electroconvulsive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroconvulsive therapy (ECT)
Study: 35246227
Drug: Midodrine 10
Normalized name: midodrine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midodrine 10 mg administered enterally every 8 hours
Study: 35020871
Drug: Racemic ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racemic ketamine (0.5 mg/kg) infusions
Study: 70648026
Drug: Ceftaroline fosamil
Normalized name: Ceftaroline fosamil
DrugBank: Ceftaroline fosamil (DB06590)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftaroline fosamil 600 mg q12h
Study: 38000564
Drug: Dapagliflozin 10
Normalized name: dapagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 10 mg
Study: 35297138
Drug: Intralesional PPD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional PPD monotherapy at 2-week intervals for up to six sessions
Study: 34768411
Drug: Sham HILT
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham HILT therapy (placebo)
Study: 32064794
Drug: Anlotinib (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib (12 mg QD from days 1 to 14 of a 21-day cycle)
Study: 33618193
Drug: Integrated exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated exposure therapy
Study: 33618193
Drug: Integrated coping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated coping skills therapy
Study: 33085787
Drug: Advances in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advances in immunotherapy for prostate cancer
Study: 36111381
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg of DIM (administered as 300 mg of DIM‐BR®) for 30 days
Study: 33765679
Drug: Low-dose exercise
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose exercise training at 4-7 days/week
Study: 39102624
Drug: Nivolumab 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 3 mg/kg every 2 weeks
Study: 37180843
Drug: Rivaroxaban 2.5
Normalized name: rivaroxaban 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 2.5 mg twice daily
Study: 38153624
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg daily
Study: 34750366
Drug: Disinfectant spray
Normalized name: Lysol Disinfectant Spray
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Disinfectant spray
Study: 34543939
Drug: Emotional intelligence
Normalized name: Intelence
DrugBank: Etravirine (DB06414)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Emotional intelligence training (twice a week for one month, then once a week for 11 months)
Study: 32065620
Drug: Serelaxin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serelaxin (30 µg/kg/day, 48 hours intravenous infusion)
Study: 36343592
Drug: Azithromycin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (20 mg/kg single oral dose)
Study: 33530942
Drug: Low-dose TXA
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose TXA
Study: 33530942
Drug: High-dose TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose TXA
Study: 32902312
Drug: Nivolumab (N)
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab (N) alone or combined with ipilimumab (I) as neoadjuvant therapy after 6 months of adjuvant therapy
Study: 32902312
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy as first-line treatment
Study: 35973802
Drug: Rituximab induction
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab induction therapy
Study: 35022178
Drug: Psychosomatic therapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychosomatic therapy, delivered by specialised exercise and physical therapists, a multimodal and tailored treatment based on the biopsychosocial model.
Study: 35022178
Drug: Psychosomatic therapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychosomatic therapy, delivered by specialised exercise and physical therapists.
Study: 35663978
Drug: Neoadjuvant trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant trastuzumab and pertuzumab treatment
Study: 32990633
Drug: Standard plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard plus weekly videoconferencing support (S+VCS)